
Elranatamab reduced the risk of disease progression or death vs standard care in patients with R/R myeloma after prior anti-CD38 therapy and lenalidomide.
Dr. Bose discusses the key findings from the COMFORT I and II trials and how the overall survival data has impacted the way he manages patients with myelofibrosis, along with the factors that most inform his treatment decisions.
Case:Â Intermediate-Risk Primary Myelofibrosis in a 68-Year-Old Woman
Clinical Presentation:
PM: No known comorbidities
Initial Clinical Workup and Diagnosis:
Initial Treatments:
